Candriam S.C.A. Has $7 Million Stock Holdings in Vera Therapeutics, Inc. $VERA

Candriam S.C.A. decreased its position in Vera Therapeutics, Inc. (NASDAQ:VERA) by 18.4% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 296,941 shares of the company’s stock after selling 66,751 shares during the quarter. Candriam S.C.A. owned 0.47% of Vera Therapeutics worth $6,996,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the company. Trexquant Investment LP grew its position in Vera Therapeutics by 187.1% during the 1st quarter. Trexquant Investment LP now owns 62,777 shares of the company’s stock worth $1,508,000 after acquiring an additional 40,913 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Vera Therapeutics in the first quarter worth $326,000. Bank of New York Mellon Corp boosted its stake in Vera Therapeutics by 1.2% in the first quarter. Bank of New York Mellon Corp now owns 143,665 shares of the company’s stock worth $3,451,000 after purchasing an additional 1,717 shares in the last quarter. Russell Investments Group Ltd. grew its holdings in shares of Vera Therapeutics by 505.1% during the first quarter. Russell Investments Group Ltd. now owns 152,918 shares of the company’s stock worth $3,673,000 after purchasing an additional 127,646 shares during the last quarter. Finally, EFG Asset Management North America Corp. increased its stake in shares of Vera Therapeutics by 49.4% in the first quarter. EFG Asset Management North America Corp. now owns 109,281 shares of the company’s stock valued at $2,623,000 after buying an additional 36,121 shares in the last quarter. 99.21% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vera Therapeutics in a research report on Wednesday, October 8th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vera Therapeutics in a research note on Thursday, September 18th. Wolfe Research reissued a “peer perform” rating on shares of Vera Therapeutics in a research note on Monday, August 4th. Bank of America assumed coverage on shares of Vera Therapeutics in a report on Thursday, October 16th. They issued a “buy” rating and a $48.00 price target for the company. Finally, JPMorgan Chase & Co. reduced their price objective on Vera Therapeutics from $53.00 to $52.00 and set an “overweight” rating on the stock in a report on Friday, November 7th. Eight investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $61.90.

Vera Therapeutics Trading Down 0.1%

Shares of NASDAQ VERA opened at $28.35 on Friday. Vera Therapeutics, Inc. has a fifty-two week low of $18.53 and a fifty-two week high of $51.27. The firm has a market capitalization of $1.81 billion, a P/E ratio of -7.11 and a beta of 1.22. The company has a debt-to-equity ratio of 0.19, a current ratio of 12.21 and a quick ratio of 12.21. The company’s 50 day simple moving average is $27.97 and its 200 day simple moving average is $24.33.

Vera Therapeutics (NASDAQ:VERA) last issued its earnings results on Wednesday, November 5th. The company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.06). During the same quarter in the prior year, the company posted ($0.85) EPS. On average, analysts predict that Vera Therapeutics, Inc. will post -2.89 EPS for the current year.

Insiders Place Their Bets

In other Vera Therapeutics news, SVP Joseph R. Young sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $29.06, for a total transaction of $435,900.00. Following the transaction, the senior vice president owned 47,839 shares in the company, valued at approximately $1,390,201.34. This trade represents a 23.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 16.30% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.